News Column

JAZZ PHARMACEUTICALS PLC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits

August 8, 2014



Item 8.01. Other Events.

On August 6, 2014, Jazz Pharmaceuticals plc (the "Company") issued a press release announcing that its wholly-owned subsidiary, Jazz Investments I Limited (the "Issuer"), intends to offer, subject to market conditions and other factors, $500 million aggregate principal amount of exchangeable senior notes due 2021 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Offering"). A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

On August 8, 2014, the Company issued a press release announcing that the Issuer had priced the Offering of $500 million aggregate principal amount of exchangeable senior notes due 2021 and that the Issuer had also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $75 million aggregate principal amount of notes from the Issuer solely to cover over-allotments, if any. A copy of the press release is filed as Exhibit 99.2 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits Exhibit Number Description 99.1 Press release, dated August 6, 2014, titled "Jazz Pharmaceuticals Announces Proposed Offering of $500 Million of Exchangeable Senior Notes." 99.2 Press release, dated August 8, 2014, titled "Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes."



--------------------------------------------------------------------------------


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters